Home > Resources > Whitepapers > State of the Global Biotech Landscape: Where the Opportunities Lie

Cell and Gene Therapy, Industrial Impact

State of the Global Biotech Landscape: Where the Opportunities Lie

December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

Spotlight

AllCells, LLC

Founded in 1998, AllCells is a biotechnology company dedicated to providing global researchers and biomanufacturing organizations with a dependable supply of biologically relevant, high quality primary cells that enable drug discovery, development, and manufacturing of cell therapies. Leveraging its expertise in hematology and immunology cell isolations, combined with on-site whole blood and bone marrow tissue collection operations, AllCells maintains direct access to a large repository of diverse donor profiles that can be further screened and qualified for biomedical applications. Utilizing its contiguous cell processing facilities, freshly collected tissue is immediately processed into purified cell types with unparalleled quality consistency. This optimal work-flow provides for the highest viability, purity, and cell count available. Fresh or cryopreserved cells are shipped worldwide, or fresh cells can be immediately utilized in fee-for-service cell-based assays, AllCellutions.

OTHER WHITEPAPERS

Multi-Specific Monoclonal Antibodies

whitePaper | February 22, 2023

The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.